EE190 Cost-Effectiveness of Dapagliflozin Alone or in Combination with Saxagliptin Added to Standard of Care for the Management of Diabetic Kidney Disease in the United States
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.439
https://www.valueinhealthjournal.com/article/S1098-3015(22)00640-4/fulltext
Title :
EE190 Cost-Effectiveness of Dapagliflozin Alone or in Combination with Saxagliptin Added to Standard of Care for the Management of Diabetic Kidney Disease in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00640-4&doi=10.1016/j.jval.2022.04.439
First page :
Section Title :
Open access? :
No
Section Order :
10384